Executive Summary
Scaling cell and gene therapy programs requires an integrated CDMO with the right manufacturing capabilities and infrastructure. This webinar provides an overview of Minaris Advanced Therapies’ global services, including cell therapy manufacturing, viral vector production, GMP systems, and technology transfer support. Watch to understand how coordinated CDMO capabilities support clinical development and commercial readiness.
Key Takeaways
– Integrated cell and gene therapy manufacturing services
– Viral vector production capabilities
– GMP infrastructure across development stages
– Technology transfer and scale-up support
Watch the webinar to explore our cell and gene therapy CDMO capabilities and capacity in detail.
About This Webinar
Advanced therapy programs face unique manufacturing challenges, from complex production processes to evolving regulatory requirements. Sponsors must ensure their CDMO partner can support clinical manufacturing today while preparing for commercial supply tomorrow.
This webinar provides an overview of Minaris Advanced Therapies’ cell and gene therapy capabilities across development and GMP manufacturing. Topics include cell therapy production, gene therapy manufacturing, viral vector production, and supporting quality systems.
The session also addresses technology transfer and scalability considerations that impact timeline predictability and long-term commercialization. By integrating manufacturing, analytical support, and global infrastructure, sponsors can reduce transfer risk and avoid mid-program disruptions.
This webinar offers a high-level look at how coordinated CDMO capabilities align technical execution with strategic growth.
Who Should Watch This Webinar?
– Cell and gene therapy developers
– CMC and operations leaders
– Teams evaluating CDMO partners
Watch nowAbout the speaker
Nithya J. Jesuraj, Ph.D.
Director of Strategic Marketing, CDMO
Nithya J. Jesuraj, Ph.D., is the Director of Strategic Marketing, CDMO, at Minaris Advanced Therapies, where she leads strategic market growth and builds high‑impact partnerships to advance cell and gene therapy programs. She is known for translating complex science into clear commercial value, elevating brand presence, and driving customer adoption across the advanced therapy ecosystem.
With 14+ years of experience spanning Resilience, Bio‑Techne, and early‑stage innovation, Dr. Jesuraj has launched multiple breakthrough products and service lines while shaping go‑to‑market strategy, technology partnerships, and commercial execution. A published scientist and frequent speaker, she blends technical depth with market insight to help companies differentiate and scale.
She holds a Ph.D. and M.S. in Biomedical Engineering from Washington University in St. Louis and a B.S. in Chemical Engineering from Cornell University.